Key result
HPSD ablation reduces atrial arrhythmia recurrence ~34% vs LPLD.
Why the study?
Although small trials comparing high power short duration and low power long duration radiofrequency ablation for atrial fibrillation exist, data from a large cohort are lacking.
Does high-power short-duration radiofrequency ablation reduce atrial arrhythmia recurrence in patients with atrial fibrillation compared to low-power long-duration ablation?
Meta-Analysis (n=3,889)
Does high-power short-duration radiofrequency ablation reduce atrial arrhythmia recurrence in patients with atrial fibrillation compared to low-power long-duration ablation?
Relative Risk: 0.66 (95% CI 0.49–0.88)
p-value: p=0.004
High-power short-duration radiofrequency ablation for atrial fibrillation is associated with lower atrial arrhythmia recurrence, faster procedural times, and fewer acute pulmonary vein reconnections compared to low-power long-duration ablation.
Supports high-power short-duration ablation for atrial fibrillation to reduce recurrences; extends prior trials via meta-analytic confirmation.
OBJECTIVE: High power short duration (HPSD) ablation strategy is proposed to be more effective than low power long duration (LPLD) for radiofrequency ablation of atrial fibrillation. Although small trials abound, data from a large cohort are lacking. This meta-analysis compares all the existing studies comparing these two approaches to evaluate perceived advantages of one over the other. METHODS: A systematic search of PubMed, EMBASE, and Cochrane databases identified studies comparing HPSD to LPLD ablation. All the analyses used the random-effects model. RESULTS: Ablation settings varied widely across 20 studies comprising 2,136 patients who underwent HPSD and 1,753 patients who underwent LPLD. The pooled incidence of atrial arrhythmia recurrence after HPSD ablation was 20% [95% confidence interval (CI): 0.16-0.25; I2=88%]. Atrial arrhythmia recurrences were significantly less frequent with HPSD ablation (incidence risk ratio=0.66; 95% CI: 0.49-0.88; I2=72%; p=0.004). Procedural, fluoroscopy, and ablation times were significantly shorter with HPSD ablation. First-pass pulmonary vein isolations (PVIs) were significantly more [odds ratio (OR)=2.94; 95% CI: 1.50-5.77; I2=89%; p=0.002), and acute pulmonary vein reconnections (PVRs) were significantly lesser (OR=0.41; 95% CI: 0.28-0.62; I2=62%; p<0.001) in the HPSD group. Although radiofrequency energy was significantly higher, esophageal thermal injuries (ETI) were lower with HPSD ablation. Acute complications, including steam-pops, were rare and statistically similar in both the groups. CONCLUSION: HPSD ablation enables faster first-pass PVI with fewer PVRs, similar ETI rates, rare collateral damage, and lower recurrence of atrial arrhythmia in the long term than LPLD. Randomized controlled studies with a larger cohort are indicated both to confirm the benefit of HPSD ablation and standardize the ablation protocol.
No takes yet. Share an insight, caveat, or question.
Khanra et al. (2021) conducted a meta-analysis in Atrial fibrillation (n=3,889). High power short duration (HPSD) radiofrequency ablation vs. Low power long duration (LPLD) radiofrequency ablation was evaluated on Atrial arrhythmia recurrence (IRR 0.66, 95% CI 0.49-0.88, p=0.004). High power short duration ablation significantly reduced atrial arrhythmia recurrences compared to low power long duration ablation (IRR 0.66; 95% CI 0.49-0.88; p=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: